Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05741489
Other study ID # STUDY00004617
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date August 10, 2022
Est. completion date March 9, 2023

Study information

Verified date February 2024
Source Emory University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Twenty participants with end stage kidney disease (ESKD) and burnt-out diabetes, and 20 non-diabetic participants with ESKD will wear a continuous glucose monitoring (CGM) device for 10 days to see if the use of CGM is a better tool to assess glycemic control than glycosylated hemoglobin (HbA1c) in patients with ESKD on dialysis.


Description:

More than 37 million adults, or 14.7% of all Americans aged 18 and older, are living with diabetes. Controlling hyperglycemia is foundational to diabetes management and is necessary to reduce the risks of chronic diabetes complications and death. Diabetic nephropathy accounts for great morbidity, as diabetes is the number one cause of chronic kidney disease (CKD) and end stage kidney disease (ESKD) in the United States. It is estimated that diabetes affects up to 40% of patients with ESKD. Assessment of glucose control in patients with advanced CKD/ESKD is complex due to changes in glucose homeostasis, potential effects on assays of glycemia, and altered pharmacokinetics of diabetes medications. Glycosylated hemoglobin (HbA1c) has been the gold standard to assess glycemic control in patients with diabetes. HbA1c reflects the average glycemic value over approximately 3 months. Although HbA1c is associated with chronic complications of diabetes in patients with normal kidney function, its predictive value is uncertain in patients with ESKD or estimated glomerular filtration rate (eGFR) <30 ml/min. HbA1c reliability in ESKD is reduced because of anemia, shortened erythrocyte lifespan, protein-energy wasting, and malnutrition-inflammation cachexia syndrome, among others. To overcome the limitations of HbA1c, alternative methods to assess long-term glycemic control have been proposed including fructosamine and glycated albumin. Fructosamine measures ketoamines formed by non-enzymatic glycation of serum proteins. It is a useful index for glycemic control over the prior 2 to 4 weeks, and some studies have reported that fructosamine more accurately reflects blood glucose control than HbA1c in anemic patients with ESKD on dialysis. However, there may be falsely low readings in the presence of hypoalbuminemia due to protein-energy wasting and in peritoneal dialysis due to dialysate protein loss. Glycated albumin is a useful marker reflecting glycemic control over the prior 2 to 4 weeks. In patients with ESKD, glycated albumin more rapidly reflects the status of blood glucose control than HbA1c. Like fructosamine, there is potential for falsely low readings in patients with peritoneal dialysis with dialysate protein losses and hypoalbuminemia. Continuous glucose monitoring (CGM) technology in the outpatient setting has transformed glucose monitoring for diabetes self-management, providing more comprehensive glycemic control data than intermittent point-of-care capillary blood glucose monitoring and HbA1c. Once progressed to ESKD, up to one fourth of patients experience resolution of their hyperglycemia, as defined by an HbA1c level of less than 6.5%, and consequently are no longer on antidiabetic agents and insulin. This phenomenon is known as "burnt-out diabetes" which is likely due to various underlying factors, including but not limited to, malnutrition, reduced clearance and degradation of insulin, decreased kidney gluconeogenesis, and accumulation of uremic toxins. These patients are likely at a greater risk of morbidity and mortality and an increased risk of hypoglycemic episodes. There is a need for further research in patients with ESKD to establish what is the most appropriate tool to assess glycemic control in those with 'burnt-out diabetes'. This study will use CGM to measure patients' glucose with real-time levels as opposed to relying on surrogate markers like HbA1c. These results can give insight into the reality of glycemic control in these patients and can impact the best monitoring and treatment for patients with burnt-out diabetes. It is not known if patients with burnt-out diabetes have complete normoglycemia or if they may have episodes of (untreated) hyperglycemia, which may be associated with poor outcomes. The researchers of this study will compare glycemic control by CGM in patients with burnt-out diabetes and non-diabetic patients with ESKD.


Recruitment information / eligibility

Status Completed
Enrollment 40
Est. completion date March 9, 2023
Est. primary completion date March 9, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Dialysis treatment for more than 3 months - HbA1c less than 6.5% at the first clinic visit - Willing to wear a CGM for 10 days Exclusion Criteria: - Have used insulin or any diabetes treatment during the last 3 months - Be pregnant or plan to become pregnant during the study - Known allergy to medical-grade adhesives - Taking acetaminophen (more than 1 gram every six hours) or hydroxyurea (may interfere with sensor membrane) - Current or anticipated use of stress steroid doses (prednisone </= 5 mg or its equivalent is allowed)

Study Design


Intervention

Device:
Continuous glucose monitoring (CGM)
The Dexcom G6 CGM system is a compact, light-weight glucose testing device that measures glucose every 5 minutes. Participants will wear the CGM with the display off for 10 days while continuing their routine dialysis sessions.

Locations

Country Name City State
United States Emory Dialysis at Greenbriar Atlanta Georgia
United States Emory Dialysis at Northside Atlanta Georgia
United States Grady Memorial Hospital Atlanta Georgia
United States Emory Dialysis at Candler Decatur Georgia

Sponsors (1)

Lead Sponsor Collaborator
Emory University

Country where clinical trial is conducted

United States, 

References & Publications (1)

Kaminski CY, Galindo RJ, Navarrete JE, Zabala Z, Moazzami B, Gerges A, McCoy RG, Fayfman M, Vellanki P, Idrees T, Peng L, Umpierrez GE. Assessment of Glycemic Control by Continuous Glucose Monitoring, Hemoglobin A1c, Fructosamine, and Glycated Albumin in — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Percent of Time in Range (TIR) Between 70-180 mg/dL Glycemic control is measured as the percentage of time that blood glucose levels are in the range of 70 and 180 mg/dL, as measured by CGM. Up to 10 days
Primary Percent of Time Above Range (Blood Glucose >180 mg/dL) Glycemic control is assessed a the percentage of time in hyperglycemia, defined as the time above range (TAR) with blood glucose measurements >180 mg/dL, as measured by CGM. Up to 10 days
Primary Percent of Time Above Range (Blood Glucose >250 mg/dL) Glycemic control is assessed a the percentage of time in hyperglycemia, defined as the time above range (TAR) with blood glucose measurements >250 mg/dL, as measured by CGM. Up to 10 days
Primary Duration of Hyperglycemia (Blood Glucose >180 mg/dL) Glycemic control is assessed as the duration of hyperglycemia with blood glucose measurements >180 mg/dL, as measured by CGM for hyperglycemia time periods of greater than 15 minutes. Up to 10 days
Primary Duration of Hyperglycemia (Blood Glucose >250 mg/dL) Glycemic control is assessed as the duration of hyperglycemia with blood glucose measurements >250 mg/dL, as measured by CGM for hyperglycemia time periods of greater than 15 minutes. Up to 10 days
Primary Number of Participants With Hyperglycemic Episodes With Blood Glucose >250 mg/dL The number of participants experiencing hyperglycemia with blood glucose levels > 250 mg/dL as measured by CGM. Up to Day 10
Primary Percent of Time Below Range (Blood Glucose <70 mg/dL) Glycemic control is assessed a the percentage of time in hypoglycemia, defined as the time below range (TBR) with blood glucose measurements < 70 mg/dL, as measured by CGM. Up to 10 days
Primary Percent of Time Below Range (Blood Glucose <54 mg/dL) Glycemic control is assessed a the percentage of time in severe hypoglycemia, defined as the time below range (TBR) with blood glucose measurements < 54 mg/dL, as measured by CGM. Up to 10 days
Primary Hypoglycemia Event Rate Hypoglycemia is defined as blood glucose < 70 mg/dL and is assessed by Dexcom G6 CGM. The hypoglycemic event rate is defined as the number of hypoglycemic events per patient per day. Up to Day 10
Primary Number of Participants With Hypoglycemic Episodes The number of participants experiencing hypoglycemia with blood glucose levels < 70 mg/dL as measured by CGM. Up to Day 10
Primary Nocturnal Hypoglycemia Event Rate Hypoglycemia is defined as blood glucose < 70 mg/dL and is assessed by Dexcom G6 CGM. A nocturnal hypoglycemia episode is defined as an episode occurring during the time interval of 10:00 Post Meridiem (PM) to 6:00 Ante Meridiem (AM). The hypoglycemic event rate is defined as the number of hypoglycemic events per patient per day. Up to Day 10
Primary Number of Participants With Nocturnal Hypoglycemic Episodes The number of participants experiencing nocturnal hypoglycemia with blood glucose levels < 70 mg/dL as measured by CGM. A nocturnal hypoglycemia episode is defined as an episode occurring during the time interval of 10:00 Post Meridiem (PM) to 6:00 Ante Meridiem (AM). Up to Day 10
Secondary Mean Daily Blood Glucose Concentration Glycemic control is assessed as mean daily glucose concentration, measured by Dexcom G6 CGM. Up to Day 10
Secondary Glycemic Variability Calculated by Mean Amplitude of Glycemic Excursions (MAGE) Mean amplitude of glycemic excursions (MAGE) is the parameter for assessing glycemic variability and is calculated based on the arithmetic mean of differences between consecutive peaks and nadirs of differences greater than one standard deviation (SD) of mean glucose values. It is designated to assess major glucose swings and exclude minor ones. Up to 10 Days
See also
  Status Clinical Trial Phase
Recruiting NCT04319185 - Assisted Peritoneal Dialysis: A Feasibility Study N/A
Recruiting NCT06056739 - Alio WEAR Study: Long-term Wear of the Alio Platform N/A
Recruiting NCT05311956 - Pain Reduction Using NEurostimulation Study N/A
Enrolling by invitation NCT05485961 - Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis Phase 2/Phase 3
Completed NCT02939586 - The Effect of Haemodialysis in Sleep Apnoea N/A
Completed NCT00792454 - Reduction of Mortality Prior to and During the First 90 Days of Dialysis Through a Renal Rehabilitation Program N/A
Recruiting NCT03586518 - Validating Novel, Non-contrast Cardiac MRI Imaging in Haemodialysis Patients
Completed NCT02513303 - Trial to Evaluate the Sirolimus-Eluting Collagen Implant on AV Fistula Outcomes Phase 3
Recruiting NCT05642156 - Hemodynamics in Chronic Hemodialysis Patients Undergoing Isolated Ultrafiltration Compared to Conventional Hemodialysis N/A
Not yet recruiting NCT05774392 - An Observational Study of Patients With Chronic Kidney Disease
Completed NCT01859871 - Evaluation of a Website on Living Kidney Donation for Hispanics N/A
Completed NCT01877863 - The Effect of Intradialytic Exercise on the Functional Capacity of Hemodialysis Patients N/A
Completed NCT00649298 - A Clinical Trial of IntensiVE Dialysis Phase 4
Recruiting NCT05836220 - Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-2 Phase 3
Completed NCT04912024 - Comparative Outcome Measures of Patients Receiving Acute Renal ThErapy Study
Completed NCT01530945 - Mapping Multidimensional Illness Trajectories of Patients With End-stage Kidney Disease N/A
Completed NCT04815850 - Phenotyping Seroconversion Following Vaccination Against COVID-19 in Patients on Haemodialysis Study
Recruiting NCT05738330 - Symptom Monitoring in Hemodialysis N/A
Completed NCT02475551 - Study to Evaluate the Safety, Tolerability, Efficacy and PK of IdeS in Kidney Transplantation Phase 2
Completed NCT00976846 - Investigation of Performance and Compatibility of the Baxter Dialyzer Xenium XPH 210 During On-line Hemodiafiltration N/A